p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, Melanie E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, Hans W., Smit, Vincent T. H. B. M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613653/
https://www.ncbi.nlm.nih.gov/pubmed/35752743
http://dx.doi.org/10.1038/s41379-022-01102-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613653/
https://www.ncbi.nlm.nih.gov/pubmed/35752743
http://dx.doi.org/10.1038/s41379-022-01102-x

Ejemplares similares